Estefanía Calvo Álvarez-rekin lankidetzan egindako argitalpenak (9)

2015

  1. Infrared Fluorescent Imaging as a Potent Tool for In Vitro, Ex Vivo and In Vivo Models of Visceral Leishmaniasis

    PLoS Neglected Tropical Diseases, Vol. 9, Núm. 3

  2. Trypanosomatids see the light: Recent advances in bioimaging research

    Drug Discovery Today, Vol. 20, Núm. 1, pp. 114-121

2014

  1. First Evidence of Intraclonal Genetic Exchange in Trypanosomatids Using Two Leishmania infantum Fluorescent Transgenic Clones

    PLoS Neglected Tropical Diseases, Vol. 8, Núm. 9

  2. Target-based vs. phenotypic screenings in Leishmania drug discovery: A marriage of convenience or a dialogue of the deaf?

    International Journal for Parasitology: Drugs and Drug Resistance, Vol. 4, Núm. 3, pp. 355-357

2013

  1. Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect

    Biochemical Pharmacology, Vol. 85, Núm. 10, pp. 1433-1440

2012

  1. Appraisal of a Leishmania major Strain Stably Expressing mCherry Fluorescent Protein for Both In Vitro and In Vivo Studies of Potential Drugs and Vaccine against Cutaneous Leishmaniasis

    PLoS Neglected Tropical Diseases, Vol. 6, Núm. 11

  2. First total synthesis of the (±)-2-methoxy-6-heptadecynoic acid and related 2-methoxylated analogs as effective inhibitors of the Leishmania topoisomerase IB enzyme

    Pure and Applied Chemistry, Vol. 84, Núm. 9, pp. 1867-1875

  3. Indotecan (LMP400) and AM13-55: Two novel indenoisoquinolines show potential for treating visceral leishmaniasis

    Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 10, pp. 5264-5270

  4. Role of trypanosomatid's arginase in polyamine biosynthesis and pathogenesis

    Molecular and Biochemical Parasitology, Vol. 181, Núm. 2, pp. 85-93